John L. Beres

Array ( [id] => 19331217 [patent_doc_number] => 20240245647 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => ISOMEROHYDROLASE INHIBITOR FOR TREATMENT OF ATROPHIC FORM OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE [patent_app_type] => utility [patent_app_number] => 18/543655 [patent_app_country] => US [patent_app_date] => 2023-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20285 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18543655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19316885 [patent_doc_number] => 20240238425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => HSD17B13 Inhibitors and/or Degraders [patent_app_type] => utility [patent_app_number] => 18/541015 [patent_app_country] => US [patent_app_date] => 2023-12-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 103 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18541015 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19297739 [patent_doc_number] => 20240226305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-11 [patent_title] => COMPOUNDS FOR TREATMENT OF TYPE 2 DIABETES [patent_app_type] => utility [patent_app_number] => 18/540091 [patent_app_country] => US [patent_app_date] => 2023-12-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10612 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18540091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18986355 [patent_doc_number] => 20240058324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => COMPOSITION FOR PREVENTION AND TREATING DEMENTIA THROUGH THE COMBINATION OF PDE5 INHIBITORS AND GLUCOCORTICOID RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/492734 [patent_app_country] => US [patent_app_date] => 2023-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4303 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18492734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081791 [patent_doc_number] => 20240108592 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => COMBINATION THERAPY WITH IMMUNOTHERAPEUTIC AGENT FOR CANCER [patent_app_type] => utility [patent_app_number] => 18/369853 [patent_app_country] => US [patent_app_date] => 2023-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5449 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18369853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083047 [patent_doc_number] => 20240109848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => PROCESS FOR THE PREPARATION OF IMIDAZOBENZODIAZEPINES [patent_app_type] => utility [patent_app_number] => 18/466730 [patent_app_country] => US [patent_app_date] => 2023-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18466730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127139 [patent_doc_number] => 20240132492 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => PYRIDOPYRIMIDINE-BASED COMPOUND AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/462373 [patent_app_country] => US [patent_app_date] => 2023-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26548 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 243 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18462373 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19318265 [patent_doc_number] => 20240239807 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-18 [patent_title] => SARS-COV2 MAIN PROTEASE INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/365919 [patent_app_country] => US [patent_app_date] => 2023-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 163929 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18365919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19096327 [patent_doc_number] => 20240115554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => METHODS FOR TREATING OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY [patent_app_type] => utility [patent_app_number] => 18/365038 [patent_app_country] => US [patent_app_date] => 2023-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 57149 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18365038 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18987729 [patent_doc_number] => 20240059698 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-22 [patent_title] => HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES [patent_app_type] => utility [patent_app_number] => 18/361062 [patent_app_country] => US [patent_app_date] => 2023-07-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43063 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18361062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18690826 [patent_doc_number] => 20230320981 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/335415 [patent_app_country] => US [patent_app_date] => 2023-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6554 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18335415 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18375936 [patent_doc_number] => 20230151017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-18 [patent_title] => THERAPEUTIC AGENTS TARGETING GPR35 [patent_app_type] => utility [patent_app_number] => 18/157686 [patent_app_country] => US [patent_app_date] => 2023-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18860 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18157686 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19570279 [patent_doc_number] => 20240374571 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-14 [patent_title] => PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS [patent_app_type] => utility [patent_app_number] => 18/687616 [patent_app_country] => US [patent_app_date] => 2022-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18687616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19543067 [patent_doc_number] => 20240360103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => COMPLEMENT INHIBITION [patent_app_type] => utility [patent_app_number] => 18/573634 [patent_app_country] => US [patent_app_date] => 2022-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83139 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18573634 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19448840 [patent_doc_number] => 20240308970 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => METHOD FOR PRODUCING ALKYLENE OXIDES [patent_app_type] => utility [patent_app_number] => 18/571783 [patent_app_country] => US [patent_app_date] => 2022-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11487 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18571783 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19658480 [patent_doc_number] => 20240425545 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-26 [patent_title] => 25-Hydroxy-Cholest-5-En-3-Sulfate Choline and Methods for Preparing, and Uses of, Same [patent_app_type] => utility [patent_app_number] => 18/572715 [patent_app_country] => US [patent_app_date] => 2022-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34433 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18572715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464091 [patent_doc_number] => 20240317760 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => TRK KINASE INHIBITOR COMPOUND AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/572862 [patent_app_country] => US [patent_app_date] => 2022-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19826 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 689 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18572862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430882 [patent_doc_number] => 20240299380 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => APPLICATION OF COMPOUND IN PREPARATION OF DRUG FOR TREATING MYELOFIBROSIS AND RELATED SYMPTOMS/SIGNS THEREOF, AND USE OF COMPOUND [patent_app_type] => utility [patent_app_number] => 18/572432 [patent_app_country] => US [patent_app_date] => 2022-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18572432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19403540 [patent_doc_number] => 20240287051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-29 [patent_title] => PROCESS FOR PREPARING AN ERK INHIBITOR [patent_app_type] => utility [patent_app_number] => 18/568772 [patent_app_country] => US [patent_app_date] => 2022-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16381 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 6 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18568772 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20083619 [patent_doc_number] => 20250213555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-03 [patent_title] => SUBSTITUTED TETRAHYDROFURAN ANALOGS AS MODULATORS OF SODIUM CHANNELS [patent_app_type] => utility [patent_app_number] => 18/566279 [patent_app_country] => US [patent_app_date] => 2022-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 98070 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18566279 [rel_patent_id] =>[rel_patent_doc_number] =>)